IRIS
FACCHINETTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 621
EU - Europa 452
AS - Asia 172
AF - Africa 1
Totale 1.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 616
SE - Svezia 159
IE - Irlanda 132
CN - Cina 103
IT - Italia 82
SG - Singapore 44
DE - Germania 28
AT - Austria 17
IN - India 10
TR - Turchia 8
FR - Francia 7
GB - Regno Unito 6
CA - Canada 5
FI - Finlandia 5
AL - Albania 3
BE - Belgio 3
IL - Israele 2
JP - Giappone 2
KH - Cambogia 2
RU - Federazione Russa 2
UA - Ucraina 2
CH - Svizzera 1
CI - Costa d'Avorio 1
ES - Italia 1
HK - Hong Kong 1
LU - Lussemburgo 1
NL - Olanda 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.246
Salva come PNG Salva come JPEG
Città #
Chandler 195
Dublin 129
Ashburn 49
Shanghai 48
New York 44
Ann Arbor 35
Boardman 30
Singapore 30
Princeton 23
Bremen 20
Vienna 17
Dearborn 14
Des Moines 12
Parma 12
Wilmington 11
Beijing 8
Nanjing 8
Pune 7
Santa Clara 6
Dallas 5
Helsinki 5
Izmir 5
Milan 5
Bologna 4
Busseto 4
Changsha 4
Kunming 4
Nanchang 4
Pavia 4
Brussels 3
Fremont 3
Grafing 3
Hebei 3
Jinan 3
Marseille 3
Nanning 3
Naples 3
Redwood City 3
Tirana 3
Washington 3
Woodbridge 3
Candiac 2
Fairfield 2
Foligno 2
Genoa 2
Guangzhou 2
Houston 2
Istanbul 2
Jiaxing 2
Minerbio 2
Norwalk 2
Reggio Emilia 2
Rome 2
Trento 2
West Jordan 2
Abidjan 1
Andover 1
Bangalore 1
Bordeaux 1
Borås 1
Bucharest 1
Cambridge 1
Dolianova 1
Florence 1
Hangzhou 1
Hefei 1
Kingston 1
Kocaeli 1
Lanzhou 1
Los Angeles 1
Luxembourg 1
Macomer 1
Ningbo 1
Pavullo Nel Frignano 1
Redmond 1
Rockville 1
Saint Petersburg 1
San Jose 1
San Mateo 1
Santa Coloma de Gramenet 1
Shenyang 1
Tappahannock 1
Wuhan 1
Zurich 1
Totale 835
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 114
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 98
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 74
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 69
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 64
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 59
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 59
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 59
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 59
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 57
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 55
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 51
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 50
Cystic brain metastases and RET fusion in lung cancer 48
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 47
Exploring the role of respiratory microbiome in lung cancer: A systematic review 47
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 45
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 44
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 44
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 39
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 38
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 36
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 24
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 16
Totale 1.296
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202059 0 0 0 6 12 12 11 6 4 5 0 3
2020/202164 1 0 4 8 7 5 1 8 13 6 9 2
2021/2022150 2 2 0 29 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024229 11 19 3 2 17 80 18 17 12 10 10 30
2024/202578 6 30 35 7 0 0 0 0 0 0 0 0
Totale 1.296